BIOPHYTIS

BIOPHYTIS (EPA:ALBPS)

30/03/2020 08:00

Biophytis Receives Approval from the Belgian Regulatory Agency to Proceed with the MYODA Program for Clinical Development of Sarconeos (BIO101) in Patients with DMD

Voir tous les communiqués de BIOPHYTIS

BIOPHYTIS (EPA:ALBPS)

24/03/2020 19:08

Biophytis Completes Recruitment of SARA-INT Phase 2b Study, Evaluating the Efficacy of Sarconeos (BIO101) in the Treatment of Sarcopenia

Voir tous les communiqués de BIOPHYTIS

BIOPHYTIS (EPA:ALBPS)

17/03/2020 08:00

Biophytis Reports 2019 Full Year Results and Provides Operational Update

Voir tous les communiqués de BIOPHYTIS

BIOPHYTIS (EPA:ALBPS)

03/03/2020 08:00

Biophytis to Present the Preliminary Results of SARA-OBS and its Impact on SARA-INT, the Phase 2b clinical study, at the 10th International Conference on Frailty and Sarcopenia Research (ICFSR 2020) in Toulouse, France

Voir tous les communiqués de BIOPHYTIS

BIOPHYTIS (EPA:ALBPS)

14/02/2020 08:01

Biophytis Trading will resume on February 14th, 2020 at 09:00 CET

Voir tous les communiqués de BIOPHYTIS

BIOPHYTIS (EPA:ALBPS)

14/02/2020 08:00

Biophytis successfully completes a € 3.3 million capital increase to strengthen its financing structure

Voir tous les communiqués de BIOPHYTIS

BIOPHYTIS (EPA:ALBPS)

13/02/2020 08:00

Biophytis shares trading is suspended pending a new press release

Voir tous les communiqués de BIOPHYTIS

BIOPHYTIS (EPA:ALBPS)

11/02/2020 08:00

Biophytis - Protocol Amendment of SARA-INT, a Phase 2b Clinical Trial of Sarconeos (BIO101) in Sarcopenia, Cleared by FDA and AFMPS

Voir tous les communiqués de BIOPHYTIS

BIOPHYTIS (EPA:ALBPS)

27/01/2020 08:00

Biophytis SARA-INT Phase 2b study, evaluating the efficacy of Sarconeos (BIO101) in sarcopenia, has now achieved over 50% patient recruitment

Voir tous les communiqués de BIOPHYTIS

BIOPHYTIS (EPA:ALBPS)

10/01/2020 19:31

Biophytis announces the issuance of a €3 million tranche of ORNANEBSA

Voir tous les communiqués de BIOPHYTIS

1
2
3
4
5
6
7
8
9
10
»